Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,877 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT07549022 | Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor | recruiting | Phase 1 / Phase 2 | 17 | Ankit Mangla, MDOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07652762 |
| IN10018 in Combination With Dalpiciclib for Progressive Meningiomas |
| recruiting |
| Phase 1 |
| 24 |
| Capital Medical UniversityOTHER |
| 1 |
| Aug 7, 2026 |
| clinicaltrials |
| NCT07751380 | Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma(MIGHTY) | recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04715191 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | recruiting | Phase 1 | 24 | Baylor College of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05210374 | Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | recruiting | Phase 1 | 24 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04999761 | AB122 Platform Study | recruiting | Phase 1 | 917 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01659203 | Proton or Photon RT for Retroperitoneal Sarcomas | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07633756 | A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy | recruiting | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06083883 | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | recruiting | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07237425 | Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma | recruiting | Phase 1 | 56 | Glonova Pharma Co., LtdINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06735820 | Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST(MEKMDM2) | recruiting | Phase 1 / Phase 2 | 45 | AeRang KimOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05957367 | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 94 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | recruiting | Phase 1 | 180 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07618377 | Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments | recruiting | Phase 1 | 10 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07602777 | A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) | recruiting | Phase 1 / Phase 2 | 113 | GlaxoSmithKlineINDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06327477 | Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 28 | Northwestern UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT07648069 | Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma | recruiting | Phase 1 | 16 | Sun Yat-sen UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07640425 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | recruiting | Phase 1 / Phase 2 | 60 | CONNEXTINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT06235125 | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children(Cytalux) | recruiting | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06957431 | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06492954 | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma(AflacST2301) | recruiting | Phase 1 | 12 | Emory UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07144254 | Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma | recruiting | Phase 1 | 24 | Emory UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07171203 | Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor | recruiting | Phase 1 | 18 | University of California, San DiegoOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06113809 | Palbociclib and Pembrolizumab in Sarcoma | recruiting | Phase 1 | 8 | John RiethOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT06889766 | NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma(LauT1) | recruiting | Phase 1 | 9 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07197645 | Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain(SOLACE) | recruiting | Phase 1 | 33 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 11, 2026source: clinicaltrials